This site is intended for US Residents only.
“I may have Hemophilia, but first and
foremost, I am DJ.”
— DJ, on ELOCTATE.
Note: This is a personal account of a MyELOCTATE Peer™. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary.

Ask your
healthcare team

about ELOCTATE.

It provides proven protection* from bleeds with a recommended starting prophylaxis infusion schedule of every 4 days. It's also the first Factor VIII with a prolonged half-life, thanks to Fc Fusion.

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

The recommended starting regimen is 50 IU/kg of ELOCTATE administered every 4 days. Adjust the regimen based on patient response, with dosing in the range of 25-65 IU/kg at 3-5 day intervals.

For children under 6 years old, the recommended starting regimen is 50 IU/kg of ELOCTATE administered twice weekly. Adjust the regimen based on patient response with dosing in the range of 25-65 IU/kg at 3-5 day intervals. More frequent or higher doses up to 80 IU/kg may be required.

CLINICAL STUDY TRIAL DESIGN

studied in 163 participants

  • Primary dosing schedule studied: infusions every 3 to every 5 days (117 people with severe Hemophilia A)
  • Other dosing schedule studied: once-weekly infusions (23 people with severe Hemophilia A)
  • On-demand group (23 people with severe Hemophilia A)

BLEED RATES FROM OTHER

DOSING REGIMEN STUDIED

SELECTED IMPORTANT SAFETY INFORMATION

  • Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Please see below for additional Important Safety Information and full Prescribing Information.

Indications and Important Safety Information

Indications

ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. ELOCTATE is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called, "inhibitors," against ELOCTATE, which may stop ELOCTATE from working properly.

The most frequently occurring side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort. These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, and if bleeding is not controlled after using ELOCTATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information.

©2017 Bioverativ. All rights reserved.